The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus
Minokoshi, Y., Alquier, T., Furukawa, N., Kim, Y.-B., Lee, A., Xue, B., Mu, J., Foufelle, F., Ferré, P., Birnbaum, M. J., et al. (2004) · Nature · doi:10.1038/nature02440 · Cited by 1,637
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Meltzer, H. Y., Matsubara, S., & Lee, J. C. (1989) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20710-8 · Cited by 1,349
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Schotte, A., Janssen, P. F. M., Gommeren, W., Luyten, W. H. M. L., Van Gompel, P., Lesage, A. S., De Loore, K., & Leysen, J. E. (1996) · Psychopharmacology · doi:10.1007/bf02245606 · Cited by 1,167
Roth, B. L., Sheffler, D. J., & Kroeze, W. K. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1346 · Cited by 1,155
McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,140
Self-citationCauses of the excess mortality of schizophrenia
Brown, S., Inskip, H., & Barraclough, B. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.3.212 · Cited by 1,087
CHOUINARD, G., JONES, B., REMINGTON, G., BLOOM, D., ADDINGTON, D., MacEWAN, G. W., LABELLE, A., BEAUCLAIR, L., & ARNOTT, W. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199302000-00004 · Cited by 876
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Olanzapine versus Placebo and Haloperidol
Beasley, C. M., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00069-p · Cited by 778
Mathur, R. (2004) · Drug Screening Methods · doi:10.5005/jp/books/10243_6 · Cited by 665
Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646
Nasrallah, H. A., Meyer, J. M., Goff, D. C., McEvoy, J. P., Davis, S. M., Stroup, T. S., & Lieberman, J. A. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.026 · Cited by 556
Self-citationGoff, D. C., Sullivan, L. M., McEvoy, J. P., Meyer, J. M., Nasrallah, H. A., Daumit, G. L., Lamberti, S., D'Agostino, R. B., Stroup, T. S., Davis, S., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.010 · Cited by 528
Self-citationNonogaki, K., Strack, A. M., Dallman, M. F., & Tecott, L. H. (1998) · Nature Medicine · doi:10.1038/2647 · Cited by 467
Atypical antipsychotics and weightgain — a systematic review
Taylor, D. M., & McAskill, R. (2000) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2000.101006416.x · Cited by 433
Obesity as a risk factor for antipsychotic noncompliance
Weiden, P. J., Mackell, J. A., & McDonnell, D. D. (2004) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00498-x · Cited by 433
Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism
Reynolds, G. P., Zhang, Z.-J., & Zhang, X.-B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08913-4 · Cited by 412
Novel antipsychotics and new onset diabetes
Wirshing, D. A., Spellberg, B. J., Erhart, S. M., Marder, S. R., & Wirshing, W. C. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00100-0 · Cited by 407
A Comparative Review On Aggression Konrad Lorenz The Territorial Imperative Robert Ardrey
Alexander, R. D., & Tinkle, D. W. (1968) · BioScience · doi:10.2307/1294259 · Cited by 397
Kim, S. F., Huang, A. S., Snowman, A. M., Teuscher, C., & Snyder, S. H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611417104 · Cited by 394
Metabolic considerations in the use of antipsychotic medications: a review of recent evidence.
Newcomer, J. W. (2007) · PubMed · Cited by 380
Gelenberg, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0101 · Cited by 356
Henderson, D. C., Cagliero, E., Copeland, P. M., Borba, C. P., Evins, A. E., Hayden, D., Weber, M. T., Anderson, E. J., Allison, D. B., Daley, T. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.19 · Cited by 319
Olanzapine‐Associated Diabetes Mellitus
Koller, E. A., & Doraiswamy, P. M. (2002) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.11.841.33629 · Cited by 303
Templeman, L. A., Reynolds, G. P., Arranz, B., & San, L. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200504000-00002 · Cited by 267
Medical Risk in Patients With Bipolar Disorder and Schizophrenia
Newcomer, J. W. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.1106e16 · Cited by 264
A review of the effect of atypical antipsychotics on weight
Nasrallah, H. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00114-2 · Cited by 243
Self-citationThe Safety of Newly Approved Medicines: Do Recent Market Removals Mean There Is a Problem?
Friedman, M. A., Woodcock, J., Lumpkin, M. M., Shuren, J. E., Hass, A. E., & Thompson, L. J. (1999) · JAMA · doi:10.1001/jama.281.18.1728 · Cited by 238
Bodyweight Gain with Atypical Antipsychotics: A Comparative Review
Wetterling, T. (2001) · Drug Safety · doi:10.2165/00002018-200124010-00005 · Cited by 231
Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications
Leslie, D. L., & Rosenheck, R. A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.9.1709 · Cited by 212
Basile, V. S., Masellis, M., McIntyre, R. S., Meltzer, H. Y., Lieberman, J. A., & Kennedy, J. L. (2001) · PubMed · Cited by 211
Reynolds, G. P., Zhang, Z., & Zhang, X. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.4.677 · Cited by 198
Matsui-Sakata, A., Ohtani, H., & Sawada, Y. (2005) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.20.368 · Cited by 191
Hyperglycemia associated with the use of atypical antipsychotics.
Lindenmayer, J., Nathan, A. M., & Smith, R. C. (2001) · PubMed · Cited by 155
Clozapine‐induced weight gain associated with the 5HT2C receptor −759C/T polymorphism
Miller, D. D., Ellingrod, V. L., Holman, T. L., Buckley, P. F., & Arndt, S. V. (2005) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30115 · Cited by 155
Dosing the antipsychotic medication olanzapine.
Nemeroff, C. B. (1997) · PubMed · Cited by 153
Managing anticholinergic side effects.
Lieberman, J. A. (2004) · PubMed · Cited by 153
Graham, K. A., Perkins, D. O., Edwards, L. J., Barrier, R. C., Lieberman, J. A., & Harp, J. B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.118 · Cited by 151
Johnson, D. E., Yamazaki, H., Ward, K. M., Schmidt, A. W., Lebel, W. S., Treadway, J. L., Gibbs, E. M., Zawalich, W. S., & Rollema, H. (2005) · Diabetes · doi:10.2337/diabetes.54.5.1552 · Cited by 151
Masaki, T., Yoshimatsu, H., Chiba, S., Watanabe, T., & Sakata, T. (2001) · Diabetes · doi:10.2337/diabetes.50.2.385 · Cited by 148
Weight change with atypical antipsychotics in the treatment of schizophrenia
Haddad, P. M. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105058378 · Cited by 148
Weight gain associated with the −759C/T polymorphism of the 5HT2C receptor and olanzapine
Ellingrod, V. L., Perry, P. J., Ringold, J. C., Lund, B. C., Bever‐Stille, K., Fleming, F. W., Holman, T. L., & Miller, D. D. (2005) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.20169 · Cited by 147
Risperidone-related Weight Gain: Genetic and Nongenetic Predictors
Lane, H., Liu, Y., Huang, C., Chang, Y., Wu, P.-L., Lu, C. ‐., & Chang, W. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000203196.65710.2b · Cited by 147
Side Effects of Atypical Antipsychotics: Extrapyramidal Symptoms and the Metabolic Syndrome
Shirzadi, A. A., & Ghaemi, S. N. (2006) · Harvard Review of Psychiatry · doi:10.1080/10673220600748486 · Cited by 146
Silvestre, J. S., & Prous, J. (2005) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2005.27.5.908643 · Cited by 143
Banerji, M. A., Lebowitz, J., Chaiken, R. L., Gordon, D., Kral, J. G., & Lebovitz, H. E. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.2.e425 · Cited by 142
Li, Z., Huang, M., Ichikawa, J., Dai, J., & Meltzer, H. Y. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300768 · Cited by 141
−759C/T genetic variation of 5HT2C receptor and clozapine-induced weight gain
Tsai, S., Hong, C., Yu, Y. W. ‐., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11705-3 · Cited by 131
Wetzel, H., Gründer, G., Hillert, A., Philipp, M., Gattaz, W. F., Sauer, H., Adler, G., Schröder, J., Rein, W., & Benkert, O. (1998) · Psychopharmacology · doi:10.1007/s002130050614 · Cited by 129
Differential metabolic effects of antipsychotic treatments
Haupt, D. W. (2006) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.06.003 · Cited by 129
Davies, M. A., Compton-Toth, B. A., Hufeisen, S. J., Meltzer, H. Y., & Roth, B. L. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2017-1 · Cited by 128
Effects of atypical antipsychotics on weight and serum lipid levels.
Meyer, J. M. (2001) · PubMed · Cited by 117
Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus
Fukagawa, K., Sakata, T., Shiraishi, T., Yoshimatsu, H., Fujimoto, K., Ookuma, K., & Wada, H. (1989) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1989.256.3.r605 · Cited by 115
Diabetes and schizophrenia 2005: are we any closer to understanding the link?
Holt, R. I. G., Bushe, C., & Citrome, L. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105058379 · Cited by 112
Citrome, L., Jaffe, A. B., Levine, J., Allingham, B., & Robinson, J. (2004) · Psychiatric Services · doi:10.1176/appi.ps.55.9.1006 · Cited by 111
−759C/genetic variation of 5HT2C receptor and clozapine-induced weight gain
Basile, V. S., Masellis, M., Luca, V. D., Meltzer, H. Y., & Kennedy, J. L. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11706-5 · Cited by 105
Olanzapine-Induced Glucose Dysregulation
Bettinger, T. L., Mendelson, S. C., Dorson, P. G., & Crismon, M. L. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.19327 · Cited by 105
Haro, J. M., & Salvador‐Carulla, L. (2006) · CNS Drugs · doi:10.2165/00023210-200620040-00003 · Cited by 98
Medical Illness and Schizophrenia
Meyer, J. M., & Nasrallah, H. A. (2003) · Medical Entomology and Zoology · Cited by 85
Self-citationTheisen, F., Hinney, A., Brömel, T., Heinzel‐Gutenbrunner, M., Martin, M., Krieg, J.-C., Remschmidt, H., & Hebebrand, J. (2004) · Psychiatric Genetics · doi:10.1097/00041444-200409000-00003 · Cited by 83
The place of partial agonism in psychiatry: recent developments
Ohlsen, R. I., & Pilowsky, L. S. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105053308 · Cited by 77
Genetic variants of the serotonin system and weight change during clozapine treatment
Hong, C., Lin, C., Yu, Y. W. ‐., Yang, K., & Tsai, S. (2001) · Pharmacogenetics · doi:10.1097/00008571-200104000-00010 · Cited by 69
Muscarinic Receptors in Schizophrenia
Dean, B., Bymaster, F. P., & Scarr, E. (2003) · Current Molecular Medicine · doi:10.2174/1566524033479654 · Cited by 66
Poyurovsky, M., Pashinian, A., Levi, A., Weizman, R., & Weizman, A. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200503000-00007 · Cited by 60
Metabolic Findings From the CATIE Trial and Their Relation to Tolerability
Nasrallah, H. A. (2006) · CNS Spectrums · doi:10.1017/s1092852900026663 · Cited by 59
Self-citationWeight decline in patients switching from olanzapine to quetiapine
Gupta, S., Masand, P. S., Virk, S., Schwartz, T. L., Hameed, A., Frank, B. L., & Lockwood, K. (2003) · Schizophrenia Research · doi:10.1016/j.schres.2003.09.016 · Cited by 59
Medical Illness and Schizophrenia
Cascella, N. G. (2004) · The Journal of Nervous and Mental Disease · doi:10.1097/01.nmd.0000144964.83457.32 · Cited by 59
Clinical Drug Monitoring in Child and Adolescent Psychiatry: Side Effects of Atypical Neuroleptics
Fleischhaker, C., Heiser, P., Hennighausen, K., Herpertz‐Dahlmann, B., Holtkamp, K., Mehler‐Wex, C., Rauh, R., Remschmidt, H., Schulz, E., & Warnke, A. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.308 · Cited by 59
Leucht, S. (2004) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145704004109 · Cited by 58
Glucose Metabolism in Patients With Schizophrenia Treated With Olanzapine or Quetiapine
Henderson, D. C., Copeland, P. M., Borba, C. P. C., Daley, T. B., Nguyen, D. D., Cagliero, E., Evins, A. E., Zhang, H., Hayden, D. L., Freudenreich, O., et al. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0513 · Cited by 56
Prevalence of the Metabolic Syndrome in Veterans with Schizophrenia
Meyer, J. M., Loh, C., Leckband, S. G., Boyd, J., Wirshing, W. C., Pierre, J. M., & Wirshing, D. A. (2006) · Journal of Psychiatric Practice · doi:10.1097/00131746-200601000-00002 · Cited by 52
Gilles, M., Wilke, A., Kopf, D., Nonell, A., Lehnert, H., & Deuschle, M. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000174994.91245.34 · Cited by 50
Schizophrenia and diabetes: Epidemiological data
Rouillon, F., & Sorbara, F. (2005) · European Psychiatry · doi:10.1016/s0924-9338(05)80189-0 · Cited by 49
Lavalaye, J., Booij, J., Linszen, D. H., Reneman, L., & van Royen, E. A. (2001) · Psychopharmacology · doi:10.1007/s002130000679 · Cited by 47
Undiagnosed Hyperglycemia in Patients Treated With Atypical Antipsychotics
Sernyak, M. J., Gulanski, B., & Rosenheck, R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n1117 · Cited by 46
Partial agonism and schizophrenia
Bolonna, A. A., & Kerwin, R. W. (2005) · The British Journal of Psychiatry · doi:10.1192/bjp.186.1.7 · Cited by 46
Arulmozhi, D. K., Dwyer, D. S., & Bodhankar, S. L. (2006) · Life Sciences · doi:10.1016/j.lfs.2006.06.016 · Cited by 42
Receptor profile of antipsychotics
Leysen, J. E. (2000) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-8448-8_4 · Cited by 34
Nasrallah, H. A. (2007) · PubMed · Cited by 34
Self-citationPharmacology of the Atypical Antipsychotic Remoxipride, a Dopamine D2Receptor Antagonist
Nadal, R. A. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00199.x · Cited by 29
Raedler, T. J. (2006) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145706006584 · Cited by 29
Gianfrancesco, F. D., Pesa, J. A., Wang, R., & Nasrallah, H. A. (2006) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp050144 · Cited by 25
Self-citation
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951
“In addition, there appears to be a direct effect of the antipsychotic medication on the ongoing development of CVD risk factors [97,116,117,130].”
BackgroundMetabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634
Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms
Reynolds, G. P., & Kirk, S. L. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.10.010 · Cited by 401
Metadata
- Authors
- Nasrallah, H. A.
- Venue
- Molecular Psychiatry
- Published
- 2007-09-11
- Volume
- 13
- Issue
- 1
- Pages
- 27-35
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2043075431
- Cited by
- 714
- References
- 88
- FWCI
- 19.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.